Measure lipoprotein-associated phospholipase A2 (Lp-PLA2), which in some studies has demonstrated more specificity than hsCRP, when it is necessary to further stratify an individual’s ASCVD risk, especially in the presence of hsCRP elevations Grade A; BEL 1 (Best Evidence Level 1)
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is categorized as a non-traditional risk factor for atherosclerotic cardiovascular disease (ASCVD).
Reference: ENDOCRINE PRACTICE Vol 23 (Suppl 2) April 2017